generic launches and risk mitigation
DESCRIPTION
Generic Launches and Risk MitigationTRANSCRIPT
![Page 1: Generic Launches and Risk Mitigation](https://reader034.vdocument.in/reader034/viewer/2022042814/554c31a7b4c905191f8b528c/html5/thumbnails/1.jpg)
GENERIC LAUNCHES AND RISK MITIGATION
Supriya Ramacha
Copyright 2012 BananaIP
Website: www.bananaip.comBlog: www.bananaip.com/sinapse-blog
![Page 2: Generic Launches and Risk Mitigation](https://reader034.vdocument.in/reader034/viewer/2022042814/554c31a7b4c905191f8b528c/html5/thumbnails/2.jpg)
AGENDA
Product launch
Risks in product launch
Risk mitigation strategies
![Page 3: Generic Launches and Risk Mitigation](https://reader034.vdocument.in/reader034/viewer/2022042814/554c31a7b4c905191f8b528c/html5/thumbnails/3.jpg)
PRODUCT LAUNCH - GENERIC
![Page 4: Generic Launches and Risk Mitigation](https://reader034.vdocument.in/reader034/viewer/2022042814/554c31a7b4c905191f8b528c/html5/thumbnails/4.jpg)
PRODUCT LAUNCH
Risk free routePatent expiryWork around
At-risk routeChallenge/Infringe
![Page 5: Generic Launches and Risk Mitigation](https://reader034.vdocument.in/reader034/viewer/2022042814/554c31a7b4c905191f8b528c/html5/thumbnails/5.jpg)
RISKS IN PRODUCT LAUNCHES
![Page 6: Generic Launches and Risk Mitigation](https://reader034.vdocument.in/reader034/viewer/2022042814/554c31a7b4c905191f8b528c/html5/thumbnails/6.jpg)
BACKGROUND
Patent Rights
Make
Use
Sell
Offer for sale
Import
Territorial
Term
![Page 7: Generic Launches and Risk Mitigation](https://reader034.vdocument.in/reader034/viewer/2022042814/554c31a7b4c905191f8b528c/html5/thumbnails/7.jpg)
PATENT RISKS
Standard Patent Term
Term extensionsPatent office delaysRegulatory delays
![Page 8: Generic Launches and Risk Mitigation](https://reader034.vdocument.in/reader034/viewer/2022042814/554c31a7b4c905191f8b528c/html5/thumbnails/8.jpg)
US-TERM EXTENSIONS
Patent process-Patent term adjustments (PTA)
One day extension - every day delayedObjective = 17 years
TypesA delays (failure to act-14-4-4-4 rule)B delays (pendency beyond 3 years)C delays (special situation)
![Page 9: Generic Launches and Risk Mitigation](https://reader034.vdocument.in/reader034/viewer/2022042814/554c31a7b4c905191f8b528c/html5/thumbnails/9.jpg)
EXAMPLE
Billy owns a US patent application for a drug “X” filed on Jan 1st 2002, for which he receives the first office action on June 1st 2003. The patent is issued on Jan 1st 2005. Silly, a generic drug maker, wants to launch “Y,” the generic version of the drug.
Launch date?
![Page 10: Generic Launches and Risk Mitigation](https://reader034.vdocument.in/reader034/viewer/2022042814/554c31a7b4c905191f8b528c/html5/thumbnails/10.jpg)
Bopi files a US patent application for a drug “Alpha” filed on Jan 1st 1998, for which it receives the first office action on June 1st 2000. The patent is issued on Jan 1st 2005. Dopi, a generic drug maker, wants to launch “Beta,” the generic version of the drug.
PTA?
![Page 11: Generic Launches and Risk Mitigation](https://reader034.vdocument.in/reader034/viewer/2022042814/554c31a7b4c905191f8b528c/html5/thumbnails/11.jpg)
EXAMPLE
Billy’s application for a drug “X” filed on Jan 1st 2002 receives the first office action on June 1st 2003.
Billy’s patent is issued on March 1st 2007 after paying the issue fee on Sept 1st 2006
Silly’s Launch date ?
Wyeth Vs Kappos case
![Page 12: Generic Launches and Risk Mitigation](https://reader034.vdocument.in/reader034/viewer/2022042814/554c31a7b4c905191f8b528c/html5/thumbnails/12.jpg)
PATENT TERM EXTENSIONS
Regulatory process-Patent term extensions (PTE)1/2 Testing phase + Approval phase
Calculationmax of 5 years extensionNMT 14 years of potential marketing exclusivity
![Page 13: Generic Launches and Risk Mitigation](https://reader034.vdocument.in/reader034/viewer/2022042814/554c31a7b4c905191f8b528c/html5/thumbnails/13.jpg)
EXAMPLE Mandoz files for a US patent on “Mentos” on April 1st
2000. The patent is issued on July 1st 2002. It subsequently files an IND application effective on July 1st 2003.
Mandoz files an NDA on July 1st 2005 and receives approval on July 1st 2006.
Possible extension? Actual extension? Launch date?
![Page 14: Generic Launches and Risk Mitigation](https://reader034.vdocument.in/reader034/viewer/2022042814/554c31a7b4c905191f8b528c/html5/thumbnails/14.jpg)
PTEs depends on the no. of potential exclusive marketing term available.
![Page 15: Generic Launches and Risk Mitigation](https://reader034.vdocument.in/reader034/viewer/2022042814/554c31a7b4c905191f8b528c/html5/thumbnails/15.jpg)
EXAMPLE Mandoz files for a US patent on “Mentos” on April 1st
2000. It files an IND application effective on July 1st 2002. The patent was issued on July 1st 2003.
Mandoz files for an NDA on July 1st 2005 and receives NDA approval on July 1st 2006.
Possible extension? Actual extension? Launch date?
Sprycel Tablets, Dasatinib,US6596746
![Page 16: Generic Launches and Risk Mitigation](https://reader034.vdocument.in/reader034/viewer/2022042814/554c31a7b4c905191f8b528c/html5/thumbnails/16.jpg)
PTE
CalculationDoes not include anytime before the date of patent
issue
Total patent term= Standard patent term + PTA + PTE
![Page 17: Generic Launches and Risk Mitigation](https://reader034.vdocument.in/reader034/viewer/2022042814/554c31a7b4c905191f8b528c/html5/thumbnails/17.jpg)
EUROPE
Regulatory process- Supplementary protection certificate (SPC)SPC Term= (1st MA date - patent filing date) - 5
years.territorial
Calculation5 years max (+6 months)NMT 15 years of potential marketing exclusivity
Total patent term = Standard Patent term + SPC
![Page 18: Generic Launches and Risk Mitigation](https://reader034.vdocument.in/reader034/viewer/2022042814/554c31a7b4c905191f8b528c/html5/thumbnails/18.jpg)
EXAMPLE
Dizer, a French applicant, obtains a national marketing approval on Jan 1st 2000, for a product protected by a patent with the filing date of Jan 1st 1990.
Dizer has also received a marketing approval in Britain on Jan 1st 1997.
Launch date?
![Page 19: Generic Launches and Risk Mitigation](https://reader034.vdocument.in/reader034/viewer/2022042814/554c31a7b4c905191f8b528c/html5/thumbnails/19.jpg)
EXAMPLE
Banana & Co. files for a patent in France on Jan 1st 1998 for a drug “Todi” and receives a national marketing approval on Jan 1st 2001. It also files for a patent in Spain on Jan 1st 1999 and receives a marketing approval in Spain on Jan 1st 2000.
Launch date in France?
![Page 20: Generic Launches and Risk Mitigation](https://reader034.vdocument.in/reader034/viewer/2022042814/554c31a7b4c905191f8b528c/html5/thumbnails/20.jpg)
REGULATORY HURDLES IN GENERIC LAUNCH
Copyright 2012 Brain League
![Page 21: Generic Launches and Risk Mitigation](https://reader034.vdocument.in/reader034/viewer/2022042814/554c31a7b4c905191f8b528c/html5/thumbnails/21.jpg)
REGULATORY HURDLES
Regulatory exclusivitiesData exclusivityOther exclusivity
![Page 22: Generic Launches and Risk Mitigation](https://reader034.vdocument.in/reader034/viewer/2022042814/554c31a7b4c905191f8b528c/html5/thumbnails/22.jpg)
US EXCLUSIVITIES
Data exclusivity- 5 years
(+1.5 to 2 years) Other exclusivity-
New clinical study exclusivity-3 yearsOrphan drug exlusivity-7 yearsPediatric exclusivity-6 months
![Page 23: Generic Launches and Risk Mitigation](https://reader034.vdocument.in/reader034/viewer/2022042814/554c31a7b4c905191f8b528c/html5/thumbnails/23.jpg)
EUROPE
Currently- 6 or 10 years
(+1 to 3 years)
New- 8+2+1 regime
Current- (2001/83/EC Directive) New- (2001/83/EC Directive as amended by 2004/27/EC)
![Page 24: Generic Launches and Risk Mitigation](https://reader034.vdocument.in/reader034/viewer/2022042814/554c31a7b4c905191f8b528c/html5/thumbnails/24.jpg)
![Page 25: Generic Launches and Risk Mitigation](https://reader034.vdocument.in/reader034/viewer/2022042814/554c31a7b4c905191f8b528c/html5/thumbnails/25.jpg)
RISK MITIGATION STRATEGIES
![Page 26: Generic Launches and Risk Mitigation](https://reader034.vdocument.in/reader034/viewer/2022042814/554c31a7b4c905191f8b528c/html5/thumbnails/26.jpg)
RISK MITIGATION STRATEGIES
Risk free launchesIdentify blocking patents- FTO analysisUnderstanding expiry
Infringement/ ChallengingIdentify evidences – Invalidation
Work aroundTechnology Landscaping
![Page 27: Generic Launches and Risk Mitigation](https://reader034.vdocument.in/reader034/viewer/2022042814/554c31a7b4c905191f8b528c/html5/thumbnails/27.jpg)
FTO ANALYSIS
Copyright 2012 Brain League
![Page 28: Generic Launches and Risk Mitigation](https://reader034.vdocument.in/reader034/viewer/2022042814/554c31a7b4c905191f8b528c/html5/thumbnails/28.jpg)
EVALUATE FTO
Search
Patent databases-blocking patent/application
Analysis
Infringement
![Page 29: Generic Launches and Risk Mitigation](https://reader034.vdocument.in/reader034/viewer/2022042814/554c31a7b4c905191f8b528c/html5/thumbnails/29.jpg)
ANALYSIS
Infringement factors
Territorial
Term
Claims
![Page 30: Generic Launches and Risk Mitigation](https://reader034.vdocument.in/reader034/viewer/2022042814/554c31a7b4c905191f8b528c/html5/thumbnails/30.jpg)
TECHNOLOGY LANDSCAPE ANALYSIS
![Page 31: Generic Launches and Risk Mitigation](https://reader034.vdocument.in/reader034/viewer/2022042814/554c31a7b4c905191f8b528c/html5/thumbnails/31.jpg)
![Page 32: Generic Launches and Risk Mitigation](https://reader034.vdocument.in/reader034/viewer/2022042814/554c31a7b4c905191f8b528c/html5/thumbnails/32.jpg)
© 2
01
1 In
telle
cture
(w
ww
.inte
llectu
rein
dia
.com
)
![Page 33: Generic Launches and Risk Mitigation](https://reader034.vdocument.in/reader034/viewer/2022042814/554c31a7b4c905191f8b528c/html5/thumbnails/33.jpg)
TECHNOLOGY MAP
![Page 34: Generic Launches and Risk Mitigation](https://reader034.vdocument.in/reader034/viewer/2022042814/554c31a7b4c905191f8b528c/html5/thumbnails/34.jpg)
THANK YOUFOR MORE DETAILS VISIT
WWW.BANANAIP.COM/SINAPSE-BLOG
A Property of BananaIP